Sanofi Stock Current Valuation

SNYN Stock  MXN 991.38  27.38  2.84%   
Valuation analysis of Sanofi helps investors to measure Sanofi's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Fairly Valued
Today
991.38
Please note that Sanofi's price fluctuation is very steady at this time. Calculation of the real value of Sanofi is based on 3 months time horizon. Increasing Sanofi's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Sanofi is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Sanofi Stock. However, Sanofi's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  991.38 Real  968.11 Hype  991.38
The intrinsic value of Sanofi's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Sanofi's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
966.60
Downside
968.11
Real Value
1,091
Upside
Estimating the potential upside or downside of Sanofi helps investors to forecast how Sanofi stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Sanofi more accurately as focusing exclusively on Sanofi's fundamentals will not take into account other important factors:
Hype
Prediction
LowEstimatedHigh
989.87991.38992.89
Details

Sanofi Company Current Valuation Analysis

Sanofi's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Enterprise Value

 = 

Market Cap + Debt

-

Cash

More About Current Valuation | All Equity Analysis

Current Sanofi Current Valuation

    
  2.69 T  
Most of Sanofi's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sanofi is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Competition

In accordance with the recently published financial statements, Sanofi has a Current Valuation of 2.69 T. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers - Major industry. The current valuation for all Mexico stocks is significantly lower than that of the firm.

Sanofi Current Valuation Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sanofi's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sanofi could also be used in its relative valuation, which is a method of valuing Sanofi by comparing valuation metrics of similar companies.
Sanofi is rated third in current valuation category among its peers.

Sanofi Fundamentals

About Sanofi Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Sanofi's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sanofi using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sanofi based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Sanofi Stock Analysis

When running Sanofi's price analysis, check to measure Sanofi's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi is operating at the current time. Most of Sanofi's value examination focuses on studying past and present price action to predict the probability of Sanofi's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi's price. Additionally, you may evaluate how the addition of Sanofi to your portfolios can decrease your overall portfolio volatility.